BIOMEDICAL (BASIC)

收缩压干预试验(SPRINT)是一项双臂、多中心、随机临床试验，旨在测试旨在将收缩压(SBP)降低到低于当前推荐目标的治疗计划是否会降低心血管疾病(CVD)的风险。将在5个临床中心网络(CCNS)的约80家诊所招募约9250名SBP大于或等于130毫米汞且至少有一种额外的心血管危险因素的参与者，为期两年，并将进行4-6年的跟踪调查。大约4300名参与者将患有慢性肾脏疾病(CKD)，约3250名年龄在75岁或以上。主要结果是首次出现心肌梗死(MI)、急性冠脉综合征(ACS)、中风、心力衰竭(HF)或心血管死亡。次要结果包括全因死亡、肾功能下降或发展为终末期肾病(ESRD)、痴呆、认知功能下降和小血管缺血性疾病。

The Systolic Blood Pressure Intervention Trial (SPRINT) is a 2-arm, multicenter, randomized clinical trial designed to test whether a treatment program aimed at reducing systolic blood pressure (SBP) to a lower goal than currently recommended will reduce cardiovascular disease (CVD) risk. About 9250 participants with SBP greater than or equal to 130 mm Hg and at least one additional CVD risk factor will be recruited at approximately 80 clinics within 5 clinical center networks (CCNs) over a 2-year period, and will be followed for 4-6 years. Approximately 4300 participants will have chronic kidney disease (CKD), and about 3250 will be aged 75 or older. The primary outcome is the first occurrence of a myocardial infarction (MI), acute coronary syndrome (ACS), stroke, heart failure (HF), or CVD death. Secondary outcomes include all-cause mortality, decline in renal function or development of end stage renal disease (ESRD), dementia, decline in cognitive function, and small vessel cerebral ischemic disease.